Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy

Clin Lung Cancer. 2022 Mar;23(2):e99-e103. doi: 10.1016/j.cllc.2021.06.012. Epub 2021 Jul 3.
No abstract available

Keywords: ALK; Acquired resistance; HER2; Lung cancer; Trastuzumab.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anaplastic Lymphoma Kinase / metabolism*
  • Carbazoles / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm / drug effects*
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Maximum Tolerated Dose
  • Piperidines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Survival Analysis
  • Trastuzumab / therapeutic use*

Substances

  • Carbazoles
  • Piperidines
  • Protein Kinase Inhibitors
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • alectinib
  • Trastuzumab